Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity2020 · 27 citations
2. 2High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods2017 · 113 citations
3. 3Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel2019 · 495 citations
4. 4Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p1851986 · 1,017 citations
5. 5Pyrotinib: First Global Approval2018 · 203 citations